These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 22871191

  • 1. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC.
    Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Jul; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 6. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ, Burnett JR.
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ.
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H.
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [Abstract] [Full Text] [Related]

  • 12. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G.
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J, Pernický M, Kiňová S.
    Vnitr Lek; 2016 Oct; 62(10):789-794. PubMed ID: 27900865
    [Abstract] [Full Text] [Related]

  • 15. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
    Niesor EJ, Chaput E, Staempfli A, Blum D, Derks M, Kallend D.
    Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

  • 18. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C.
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [Abstract] [Full Text] [Related]

  • 19. [HDL and CETP in atherogenesis].
    Pöss J, Böhm M, Laufs U.
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.